GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)

(2012) M. Meggendorfer et al.   BLOOD

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome

(2012) S.-J. Zhang et al.   BLOOD

Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A

(2011) A. M. Jankowska et al.   BLOOD

Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia

(2011) Mignon L. Loh   BRITISH JOURNAL OF HAEMATOLOGY

Aberrant phosphorylation of STAT5 by granulocyte-macrophage colony-stimulating factor in infant cytomegalovirus infection mimicking juvenile myelomonocytic leukemia

(2011) Nobuhiro Nishio et al.   LEUKEMIA RESEARCH

A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia

(2011) Apostolos Klinakis et al.   NATURE

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia

(2010) J. Wang et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Molecular basis of cytokine receptor activation

(2010) Angel F Lopez et al.   IUBMB LIFE

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1

(2010) Alexander Kohlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease

(2009) T. R. Hercus et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

(2008) D. E. Rollison et al.   BLOOD

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

(2008) Hagop Kantarjian et al.   CANCER

Going with the Flow: JAK-STAT Signaling in JMML

(2008) Demetrios Kalaitzidis et al.   CANCER CELL

Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates

(2008) Nikesh Kotecha et al.   CANCER CELL

The Structure of the GM-CSF Receptor Complex Reveals a Distinct Mode of Cytokine Receptor Activation

(2008) Guido Hansen et al.   CELL

Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes

(2008) Lucia Conti et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Aberrant GM-CSF signal transduction pathway in juvenile myelomonocytic leukemia assayed by flow cytometric intracellular STAT5 phosphorylation measurement

(2008) G Gaipa et al.   LEUKEMIA

Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia

(2008) P D Emanuel   LEUKEMIA